SGLT2 Inhibitors
Sort by:
Inova Cherry Blossom Virtual Cardiovascular Symposium 2021
The Dangerous Intersection of Diabetes and Heart Disease
FEATURING
Darren K. Mcguire
- 76 views
- June 8, 2021
Courage and Innovation Symposium: Heart Failure & Heart Transplantation
SGLT2 Inhibitors: Not Just for Diabetics Anymore
FEATURING
Rachel Lavelle, Pharmd
- 223 views
- May 17, 2021
- 3
Emory Diabetes Education Training Academy
SGLT-2 Inhibitors And T2D Care: What Is the Mechanism Of Action? What Is the Efficacy as Monotherapy?
FEATURING
Sol Jacobs
- 222 views
- April 28, 2021
- 3
Emory Diabetes Education Training Academy
Evolution of SGLT2-Inhibitors and GLP1-RA's Relating to Macrovascular Outcomes
FEATURING
Francisco Pasquel
- 106 views
- April 26, 2021
Emory Diabetes Education Training Academy
SGLT2-i Impact on Renal or HF Outcomes: What Is Observed in Non-Diabetic Patients?
FEATURING
Francisco Pasquel
- 264 views
- April 26, 2021
4th Annual Cardiovascular Conference: Advances in Cardiovascular Disease - from Prevention to Intervention
SGLT2 Antagonists: How Has Their Role Expanded?
FEATURING
Eugenia Gianos
- 1,181 views
- April 20, 2021
- 13
16th Annual Heart Failure Holiday Symposium
New Treatment Approaches to HFrEF: When to Use SGLT2, Vericiguat, Omecamtiv Mecarbil and IV Iron?
FEATURING
Mark Drazner
- 1,116 views
- February 18, 2021
- 12
San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians
Approaches to Treating Diabetes that Reduce CV Events: How Effective Are DPP-4 Inhibitors, GLP1-Receptor Agonists and SGLT-2 Inhibitors in Reducing MACE and Preventing HF Events?
FEATURING
Jia Shen
- 337 views
- February 5, 2021
- 4
San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians
Recognizing and Treating HFpEF: How Helpful Are MRAs, ARNi and SGLT2 Inhibitors for Treating Patients? What Have We Learned From The PARADIGM and PARAGON Trials?
FEATURING
Barry Greenberg
- 2,010 views
- February 5, 2021
- 22